Scilex Holding (SCLX) Short-term Investments (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Short-term Investments of $200000.0 for Q1 2026, down 96.77% on a QoQ basis from $6.2 million in Q4 2025.
Scilex Holding (SCLX) Short-term Investments (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Short-term Investments for 4 consecutive years, with $200000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments changed N/A year-over-year to $200000.0; the TTM figure through Mar 2026 stood at $200000.0 (changed N/A YoY), while the FY2025 annual figure was $6.2 million, changed N/A from the prior year.
- Short-term Investments came in at $200000.0 for Q1 2026 at Scilex Holding, down from $6.2 million in the prior quarter.
- The five-year high for Short-term Investments was $141.7 million in Q2 2022, with the low at $34961.0 in Q3 2022.
- Average Short-term Investments over 3 years is $57.7 million, with a median of $6.2 million recorded in 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 6.20 Mn |
| Sep 30, 2022 | 34,961.00 |
| Jun 30, 2022 | 141.69 Mn |
| Mar 31, 2022 | 140.45 Mn |
| Dec 31, 2021 | 139.41 Mn |